资金借道医药ETF抄底，规模居标的第一的生物医药ETF(159859)盘中净申购超1.4亿份，全市场独家品种创新药ETF天弘(517380)逆势吸金

格隆汇2025-06-26

医药板块回调之际，资金借道ETF逆势抄底，生物医药ETF(159859)盘中净申购超1.4亿份。生物医药ETF(159859)及联接基金(A类011040， C类011041)是同标的规模第一、流动性最好的产品，年初至今涨幅居标的第一，其跟踪生物医药指数，均衡布局医药板块，覆盖创新药、疫苗、血制品等细分品种。创新药ETF天弘(517380)昨日净流入529万元资金流入，近10个交易日获4465...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2546274853?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-06-26 11:22","share_image_url":"https://static.laohu8.com/6b8fa6424aebe95f6781d04ef17a1852","id":"2546274853","market":"sh","top_or_hot":-1,"title":"资金借道医药ETF抄底，规模居标的第一的生物医药ETF(159859)盘中净申购超1.4亿份，全市场独家品种创新药ETF天弘(517380)逆势吸金","media":"格隆汇","content":"<div>\n<p>医药板块回调之际，资金借道ETF逆势抄底，生物医药ETF(159859)盘中净申购超1.4亿份。\n生物医药ETF(159859)及联接基金(A类011040， C类011041)是同标的规模第一、流动性最好的产品，年初至今涨幅居标的第一，其跟踪生物医药指数，均衡布局医药板块，覆盖创新药、疫苗、血制品等细分品种。\n创新药ETF天弘(517380)昨日净流入529万元资金流入，近10个交易日获4465...</p>\n\n<a href=\"https://www.gelonghui.com/rss/live/live.xml\">网页链接</a>\n\n</div>\n","source":"live_gelonghui","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>资金借道医药ETF抄底，规模居标的第一的生物医药ETF(159859)盘中净申购超1.4亿份，全市场独家品种创新药ETF天弘(517380)逆势吸金</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n资金借道医药ETF抄底，规模居标的第一的生物医药ETF(159859)盘中净申购超1.4亿份，全市场独家品种创新药ETF天弘(517380)逆势吸金\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-06-26 11:22 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.gelonghui.com/rss/live/live.xml><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>医药板块回调之际，资金借道ETF逆势抄底，生物医药ETF(159859)盘中净申购超1.4亿份。\n生物医药ETF(159859)及联接基金(A类011040， C类011041)是同标的规模第一、流动性最好的产品，年初至今涨幅居标的第一，其跟踪生物医药指数，均衡布局医药板块，覆盖创新药、疫苗、血制品等细分品种。\n创新药ETF天弘(517380)昨日净流入529万元资金流入，近10个交易日获4465...</p>\n\n<a href=\"https://www.gelonghui.com/rss/live/live.xml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0316494557.USD","symbol_name":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","start_time":0,"source_url":"https://www.gelonghui.com/rss/live/live.xml","article_id":"2546274853","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2546274853","pubTimestamp":1750908172,"columns":[],"sourceInfo":{"source_id":"live_gelonghui","name":"格隆汇"},"weMediaInfo":null,"summary":"医药板块回调之际，资金借道ETF逆势抄底，生物医药ETF(159859)盘中净申购超1.4亿份。\n生物医药ETF(159859)及联接基金(A类011040， C类011041)是同标的规模第一、流动","collect":0,"end_time":0,"defaultTopTitle":"gelonghui.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159217":"港创新药","159646":"疫苗","159859":"生物药30","159938":"医药","159982":"中证500","159992":"创新药","161027":"证券","161726":"生物医药","399300":"沪深300","399441":"生物医药","512290":"生物医药ETF国泰","515120":"创新药ETF广发","600276":"恒瑞医药","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","09939":"开拓药业-B","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LLY":"礼来","07226":"南方两倍做多恒科","BK4581":"高盛持仓","BK4532":"文艺复兴科技持仓","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","01276":"恒瑞医药","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","HSCEI":"国企指数","NVO":"诺和诺德","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","CXO":"康休","BK0239":"医药制造","HSTECH":"恒生科技指数","LU2750360997.AUD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (AUDHDG) INC","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","SG9999001176.USD":"United Global Healthcare Acc USD","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","FDN":"First Trust Dow Jones Internet I","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","YANG":"三倍做空富时中国ETF-Direxion","06978":"永泰生物-B","LU1917777945.USD":"安联专题基金Cl AT Acc","CXO.AU":"CORE LITHIUM LTD"},"translate_title":"Funds borrowed pharmaceutical ETFs to buy bottoms. The largest biomedical ETF (159859) had a net intraday subscription of more than 140 million shares. Tianhong (517380), an exclusive innovative drug ETF in the whole market, bucked the trend and attracted gold","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159217":1,"159646":1,"159859":1,"159938":1,"159982":1,"159992":1,"161027":1,"161726":1,"399300":1,"399441":1,"512290":1,"515120":1,"600276":1,"YANG":1,"CXO.AU":1,"06978":1,"01276":1,"LLY":1,"NVO":1,"HSTECH":1,"09939":1,"HSCEI":1,"07226":1,"FDN":1,"CXO":1},"content_text":"医药板块回调之际，资金借道ETF逆势抄底，生物医药ETF(159859)盘中净申购超1.4亿份。\n生物医药ETF(159859)及联接基金(A类011040， C类011041)是同标的规模第一、流动性最好的产品，年初至今涨幅居标的第一，其跟踪生物医药指数，均衡布局医药板块，覆盖创新药、疫苗、血制品等细分品种。\n创新药ETF天弘(517380)昨日净流入529万元资金流入，近10个交易日获4465万元资金净流入。\n全市场独家品种·创新药ETF天弘(517380)及联接基金(A类014564， C类014565)是全市场唯一跟踪恒生沪深港创新药精选50指数的ETF，实现了A股+港股、创新药+CXO全面覆盖，该产品年内涨幅超24%。\n医药板块今年迎来多重利好：\n1.6月20日-6月23日，全球规模最大的糖尿病会议——ADA大会在美国芝加哥召开，汇聚了诺和诺德、礼来等跨国巨头及恒瑞医药、先为达生物等中国创新药企，逾40项药物临床数据集中披露，涵盖降糖减重疗效、新型靶点等减重代谢领域核心议题。\n2.荣昌生物公告，公司将具有自主知识产权的泰它西普有偿许可给美国Vor Bio公司，美国Vor Bio公司将获得在除大中华区以外的全球范围内开发和商业化的独家权利。\n3.6月25日，《学习时报》刊文称，创新药不仅是医药领域的科研创新成果，更关乎国家发展的全局，加快创新药研发具有多重战略意义。\n4.ASCO年会常规摘要发布，中国研究者共计70余项原创研究入选口头报告。\n湘财证券认为，创新药十年持续投入后迎来成果兑现期，临床数据不断读出、海外授权持续落地及商业化加速有望为板块持续提供基本面支撑，短期回调迎来布局良机，2025年国内创新药产业有望迎来拐点，产业运行趋势由资本驱动转向盈利驱动，板块有望迎来业绩与估值双重修复投资机会。","kind":"live","is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2546274853","isCrawlerRequest":true}